KR20190021311A - 알츠하이머병의 치료 방법 - Google Patents

알츠하이머병의 치료 방법 Download PDF

Info

Publication number
KR20190021311A
KR20190021311A KR1020197000443A KR20197000443A KR20190021311A KR 20190021311 A KR20190021311 A KR 20190021311A KR 1020197000443 A KR1020197000443 A KR 1020197000443A KR 20197000443 A KR20197000443 A KR 20197000443A KR 20190021311 A KR20190021311 A KR 20190021311A
Authority
KR
South Korea
Prior art keywords
subject
antibody
body weight
administering
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197000443A
Other languages
English (en)
Korean (ko)
Inventor
브랜든 필립 부트
제프리 조지프 세비니
레슬리 루진 윌리엄스
Original Assignee
바이오겐 인터내셔널 뉴로사이언스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 인터내셔널 뉴로사이언스 게엠베하 filed Critical 바이오겐 인터내셔널 뉴로사이언스 게엠베하
Priority to KR1020237040938A priority Critical patent/KR20230165883A/ko
Publication of KR20190021311A publication Critical patent/KR20190021311A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020197000443A 2016-06-07 2017-06-06 알츠하이머병의 치료 방법 Ceased KR20190021311A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237040938A KR20230165883A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US62/346,818 2016-06-07
US201662435531P 2016-12-16 2016-12-16
US62/435,531 2016-12-16
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040938A Division KR20230165883A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Publications (1)

Publication Number Publication Date
KR20190021311A true KR20190021311A (ko) 2019-03-05

Family

ID=59067640

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197000443A Ceased KR20190021311A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법
KR1020237040938A Ceased KR20230165883A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237040938A Ceased KR20230165883A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Country Status (12)

Country Link
US (2) US20200308259A1 (https=)
EP (1) EP3464350A1 (https=)
JP (3) JP2019517540A (https=)
KR (2) KR20190021311A (https=)
CN (3) CN114796481A (https=)
AU (2) AU2017276656A1 (https=)
BR (1) BR112018075300A2 (https=)
CA (1) CA3026598A1 (https=)
IL (1) IL263433B2 (https=)
MA (1) MA45149A (https=)
MX (1) MX2018015022A (https=)
WO (1) WO2017211827A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
US20220177560A1 (en) 2019-03-26 2022-06-09 Janssen Pharmaceutica Nv Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
MX2022004678A (es) * 2019-10-22 2022-08-15 Biogen Ma Inc Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
WO2022261026A2 (en) * 2021-06-07 2022-12-15 Biogen Ma Inc. Methods for treating alzheimer's disease
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
MX2024005999A (es) * 2021-11-19 2024-05-30 Ap Biosciences Inc Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2468770T (lt) * 2006-07-14 2018-05-25 Ac Immune S.A. Humanizuotas antikūnas prieš beta amiloidą
KR20120017469A (ko) 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
RU2689674C2 (ru) * 2012-10-15 2019-05-28 Медиммьюн Лимитед Антитела к бета-амилоиду
CN105979962A (zh) * 2012-12-07 2016-09-28 比奥根国际神经科学公司 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
PT2935326T (pt) 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
RU2724190C2 (ru) * 2014-02-08 2020-06-23 Дженентек, Инк. Способы лечения болезни альцгеймера
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
JP2019517540A (ja) 2019-06-24
IL263433B2 (en) 2024-03-01
US20200308259A1 (en) 2020-10-01
AU2017276656A1 (en) 2018-12-13
AU2024216442A1 (en) 2024-10-17
JP2022145965A (ja) 2022-10-04
CN114931635A (zh) 2022-08-23
WO2017211827A1 (en) 2017-12-14
CA3026598A1 (en) 2017-12-14
JP2025160337A (ja) 2025-10-22
CN109476730A (zh) 2019-03-15
KR20230165883A (ko) 2023-12-05
MA45149A (fr) 2019-04-10
EP3464350A1 (en) 2019-04-10
IL263433A (en) 2019-01-31
MX2018015022A (es) 2019-08-14
US20220281963A1 (en) 2022-09-08
IL263433B1 (en) 2023-11-01
CN114796481A (zh) 2022-07-29
BR112018075300A2 (pt) 2019-04-30

Similar Documents

Publication Publication Date Title
US20260091109A1 (en) Method for Treating Alzheimer's Disease
US20220281963A1 (en) Methods for treating alzheimer's disease
KR20220084095A (ko) 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
WO2022261026A2 (en) Methods for treating alzheimer's disease
NZ788486A (en) Methods for treating Alzheimer's disease
WO2026015877A1 (en) Fluid biomarker
EA051351B1 (ru) Способ лечения болезни альцгеймера

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200605

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220729

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230629

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220729

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231128